<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671658</url>
  </required_header>
  <id_info>
    <org_study_id>ID02-230</org_study_id>
    <nct_id>NCT00671658</nct_id>
  </id_info>
  <brief_title>Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Phase II Study of The Modified Hyper-CVAD Program for Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if intensive chemotherapy (with&#xD;
      monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed&#xD;
      by monthly maintenance chemotherapy for 2 Â½ years can improve or cure acute lymphoblastic&#xD;
      leukemia (ALL) or lymphoblastic lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The modified hyper-CVAD regimen is a combination of chemotherapy drugs including&#xD;
      cyclophosphamide, vincristine, Adriamycin, dexamethasone and pegylated asparaginase given&#xD;
      together for one &quot;course&quot; of treatment. This alternates with a course or combination of the&#xD;
      chemotherapy drugs methotrexate, cytarabine (ara-C), and pegylated asparaginase. Rituximab is&#xD;
      a protein (monoclonal antibody) that attaches to the surface of the leukemia or lymphoma&#xD;
      cells, which have a marker, called &quot;CD20&quot;.&#xD;
&#xD;
      Before treatment starts, participants will have a complete physical exam, including blood&#xD;
      (about 8 teaspoons) tests. A chest X-ray may be taken. CT scans may be taken if needed. A&#xD;
      bone marrow sample will be taken through a large needle in the hipbone. Women able to have&#xD;
      children must have a negative blood pregnancy test. An ECG (tracing of the heart) and a&#xD;
      cardiac scan or echocardiogram may be taken to check the heart function.&#xD;
&#xD;
      Participants will receive these 2 kinds of intensive chemotherapy courses for a total of 8&#xD;
      courses as long as they are able to tolerate them. Chemotherapy courses will be given through&#xD;
      a large vein by a central venous catheter (a plastic tube usually placed under the&#xD;
      collarbone) or a long-line catheter (a plastic tube usually placed in the upper arm).&#xD;
&#xD;
      During treatment, participants will have a physical exam and undergo blood tests (about 1&#xD;
      tablespoon each) at least twice a week. After the first course of chemotherapy, the tests&#xD;
      done before treatment will be repeated to check for response. In patients with acute&#xD;
      lymphoblastic leukemia or lymphoblastic lymphoma with marrow disease, a bone marrow sample&#xD;
      will be repeated about 2 and 3 weeks from the beginning of treatment to check the response.&#xD;
&#xD;
      Course 1 (odd courses) will start by giving rituximab by vein over 6 hours on Day 1 and Day&#xD;
      11 for patients whose leukemia or lymphoma expresses CD20. Participants will receive the&#xD;
      drugs acetaminophen (Tylenol) and diphenhydramine hydrochloride (Benadryl) 30-60 minutes&#xD;
      before each dose of rituximab. This will be done to lessen the risk of fever, chills, and&#xD;
      allergic reactions. Usually, the first dose of rituximab requires about 6 to 8 hours to&#xD;
      complete. If side effects do occur during the infusion, participants will be observed for an&#xD;
      additional 2 hours after the rituximab is given. Then, the cyclophosphamide will be given as&#xD;
      described below.&#xD;
&#xD;
      Other participants who do not have the CD20 marker will start Course 1 with cyclophosphamide&#xD;
      given by vein over 2-3 hours every 12 hours. This will be given for 6 doses over 3 days (Days&#xD;
      1,2, and 3). Pegylated asparaginase will be given by vein over 30 minutes on Day 1.&#xD;
      Adriamycin will be given by vein over 24 hours on Day 4. Vincristine will be given by vein&#xD;
      over 15 to 30 minutes on Days 1 and 11. Dexamethasone (a steroid) will be given by mouth or&#xD;
      by vein on Days 1 to 4 and 11 to 14.&#xD;
&#xD;
      Pegfilgrastim (a growth colony stimulating factor) will be given after each course of&#xD;
      chemotherapy is finished. It is given to help with rapid recovery of the white blood cells in&#xD;
      the normal marrow. Pegfilgrastim will be injected under the skin within 72 hours of&#xD;
      completion of each cycle of chemotherapy. Filgrastim, a shorter active form of pegfilgrastim&#xD;
      may be used instead or added later if needed.&#xD;
&#xD;
      Treatment to protect the brain will be given inside the spinal using lumbar punctures (spinal&#xD;
      taps) with chemotherapy, including methotrexate around day 2 and cytarabine (ara-C) about day&#xD;
      7 of the course. This is done to decrease the risk that the leukemia or lymphoma will develop&#xD;
      there. If there is leukemia or lymphoma in the spinal fluid at the time of the first spinal&#xD;
      tap, then the treatments will be given more frequently.&#xD;
&#xD;
      For patients aged 60 years or older, this first course of chemotherapy will be given in a&#xD;
      protective isolation room to decrease the risk of infection(s).&#xD;
&#xD;
      During Course 2, participants whose leukemia expresses CD20 will receive rituximab by&#xD;
      infusion over 4 hours on Days 1 and 8. Other participants who do not have CD20 on the&#xD;
      leukemia cells will start with methotrexate by vein over 24 hours on Day 1. Cytarabine&#xD;
      (ara-C) will be given by vein over 2 hours every 12 hours for 4 doses (Days 2 and 3).&#xD;
      Vincristine will be given by vein over 15 to 30 minutes on Days 1 and 8. Pegylated&#xD;
      asparaginase will be given by vein over 30 minutes on Day 4 or 5 after the methotrexate has&#xD;
      cleared (as checked by blood tests).&#xD;
&#xD;
      Citrovorum factor (leucovorin), an antidote for side effects of methotrexate, will be given&#xD;
      by vein or by mouth for 2-3 days (Day 2 and on). Pegfilgrastim will be given as in Course 1&#xD;
      (24-72 hours after the chemotherapy is finished). The treatment to protect the brain inside&#xD;
      the spinal fluid will be given as in Course 1 on Days 2 and 7.&#xD;
&#xD;
      The rest of the chemotherapy will switch between hyper-CVAD and pegylated asparaginase&#xD;
      (Courses 3, 5, and 7) and methotrexate,cytarabine (ara-C), vincristine, and pegylated&#xD;
      asparaginase (Courses 4, 6, and 8) to complete a total of 8 courses. Participants whose&#xD;
      leukemia expresses CD20 will receive a total of 12 doses (2 per each of the first four&#xD;
      courses, then one with the last four courses) of rituximab.&#xD;
&#xD;
      After the 8 courses, patients with lymphoblastic lymphoma who had enlarged lymph glands in&#xD;
      the mediastinum may receive radiation to the chest. Those participants not needing radiation&#xD;
      will proceed to monthly maintenance chemotherapy. This includes daily 6-mercaptopurine taken&#xD;
      by mouth, weekly methotrexate by vein or mouth, monthly vincristine by vein, and&#xD;
      dexamethasone by mouth for 5 days every month. Participants with lymphoblastic lymphoma will&#xD;
      start maintenance chemotherapy after finishing radiation.&#xD;
&#xD;
      Maintenance chemotherapy will be given for a total of 30 months, and will be interrupted by 2&#xD;
      periods of intensive chemotherapy courses. The first will be at six months into the&#xD;
      maintenance program starting first with hyper-CVAD (like Course 1) except without pegylated&#xD;
      asparaginase). The following months, participants will receive methotrexate by vein on Day 1,&#xD;
      vincristine by vein on Day 1, and pegylated asparaginase by vein on Day 2. Participants will&#xD;
      receive this sequence of 2 chemotherapy courses again 18 months into the maintenance program.&#xD;
      Participants with the CD20 marker will receive rituximab during the maintenance chemotherapy&#xD;
      (with the vincristine during months 1, 3, 6, 7, 10, 13, 18 &amp; 19).&#xD;
&#xD;
      After one or two courses of therapy, the response to the treatment will be evaluated. If the&#xD;
      leukemia or lymphoma is responding, the therapy will be continued. Participants will be taken&#xD;
      off study if the leukemia or lymphoma starts to get worse.&#xD;
&#xD;
      After completion of treatment, participants will have a complete physical exam, including&#xD;
      blood tests (about 8 teaspoons). If needed, a chest X-ray or CT scan will be done. A bone&#xD;
      marrow sample will be taken through a large needle. Patients will then return every 3 to 6&#xD;
      months for a checkup, including blood tests and bone marrow aspiration. X-rays may be&#xD;
      repeated if needed.&#xD;
&#xD;
      An Ommaya reservoir may also be placed surgically as a route to treat leukemia in the brain&#xD;
      or to decrease the risk of leukemia in patients who have difficulty with the spinal&#xD;
      treatments. An Ommaya reservoir is a tube inserted under the skin of the scalp that enters&#xD;
      into the spinal fluid cavity of the brain.&#xD;
&#xD;
      Treatment will be given on an inpatient basis for the 8 intensive cycles of chemotherapy, or&#xD;
      as indicated by the clinical condition. The maintenance treatments will be given as an&#xD;
      outpatient but may be given as an inpatient if needed.&#xD;
&#xD;
      This is an investigational study. All of the drugs are commercially available. Their use&#xD;
      together in this study is investigational. About 280 patients will take part in this study.&#xD;
      All will be enrolled at M. D. Anderson Cancer Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Response</measure>
    <time_frame>Response assessed following first 21 day course up to end of treatment with 8 cycles, up to 210 days</time_frame>
    <description>Response - Complete remission (CR): Normalization peripheral blood &amp; bone marrow 5% or &lt;blasts in normocellular or hypercellular marrow granulocyte count of 1x10^9/L or &gt; &amp; platelet count &gt;100x10^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count &lt;100x10^9/L. CR with incomplete recovery (CRi): CR but platelet count &lt;100x10^9/L or absolute neutrophil count &lt; 1x10^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphoma (&amp; ALL subtypes with extramedullary disease): CR - disappearance all known disease. PR - &gt;50% decrease in tumor size using sum of product, includes 50% volume decrease in lesions measurable in 3 dimensions. No Response (NR) - No significant change (includes stable disease). Lesions decreased size but &lt;50% or lesions with slight enlargement &lt;25% increase in size. Progressive Disease (PD): Appearance new lesions, 25% or &gt; increase in size existing lesions (&gt;50% if 1 lesion &amp; &lt;2).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide (CTX)</intervention_name>
    <description>300 mg/m2 by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2 by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>2 mg by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar Pfs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg by vein or by mouth (P.O.)</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate (MTX)</intervention_name>
    <description>12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7&#xD;
200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Rheumatrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg intrathecal for Courses 1,3,5,7&#xD;
3 gm/m2 by vein for Courses 2,4,6,8</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>DepoCyt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>10 ug/kg subcutaneous injection</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>600 mg/m2 a day by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated asparaginase</intervention_name>
    <description>2000 International units/m2 by vein</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Pegaspargase</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>Polyethylene Glycol Conjucated Lasparaginase-H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>6 mg (flat dose) within 72 hrs after completion of chemotherapy</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Neulasta</other_name>
    <other_name>PEG-G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solumedrol</intervention_name>
    <description>40 mg by vein for Courses 2,4,6,8</description>
    <arm_group_label>HYPER-CVAD</arm_group_label>
    <other_name>Methylprednisolone</other_name>
    <other_name>Depo-Medrol</other_name>
    <other_name>Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed, previously untreated Acute Lymphoblastic Leukemia (ALL) or&#xD;
             lymphoblastic lymphoma, or having achieved Complete Remission (CR) with one course of&#xD;
             induction chemotherapy.&#xD;
&#xD;
          2. Failure to one induction course of chemotherapy are eligible, but these patients will&#xD;
             be analyzed separately.&#xD;
&#xD;
          3. All ages are eligible.&#xD;
&#xD;
          4. Zubrod performance less than or equal to 3&#xD;
&#xD;
          5. Adequate liver function (bilirubin &lt;/= 3.0 mg/dl unless considered due to tumor) and&#xD;
             renal function (creatinine &lt;/= 3.0 mg/dl, unless considered due to tumor).&#xD;
&#xD;
          6. Adequate cardiac function as assessed by history and physical examination.&#xD;
&#xD;
          7. No active co-existing malignancy with life expectancy less than 12 months due to that&#xD;
             malignancy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) N/A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan O'Brien, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2020</results_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>HYPER-CVAD</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Remission Duration</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Asparaginase</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Leukine</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Vincristine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 11/02/2002 to 8/28/2012. All recruitment done at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HYPER-CVAD</title>
          <description>Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m^2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hours after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HYPER-CVAD</title>
          <description>Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m^2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hours after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="16" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Response</title>
        <description>Response - Complete remission (CR): Normalization peripheral blood &amp; bone marrow 5% or &lt;blasts in normocellular or hypercellular marrow granulocyte count of 1x10^9/L or &gt; &amp; platelet count &gt;100x10^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count &lt;100x10^9/L. CR with incomplete recovery (CRi): CR but platelet count &lt;100x10^9/L or absolute neutrophil count &lt; 1x10^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphoma (&amp; ALL subtypes with extramedullary disease): CR - disappearance all known disease. PR - &gt;50% decrease in tumor size using sum of product, includes 50% volume decrease in lesions measurable in 3 dimensions. No Response (NR) - No significant change (includes stable disease). Lesions decreased size but &lt;50% or lesions with slight enlargement &lt;25% increase in size. Progressive Disease (PD): Appearance new lesions, 25% or &gt; increase in size existing lesions (&gt;50% if 1 lesion &amp; &lt;2).</description>
        <time_frame>Response assessed following first 21 day course up to end of treatment with 8 cycles, up to 210 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HYPER-CVAD</title>
            <description>Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m^2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hours after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response</title>
          <description>Response - Complete remission (CR): Normalization peripheral blood &amp; bone marrow 5% or &lt;blasts in normocellular or hypercellular marrow granulocyte count of 1x10^9/L or &gt; &amp; platelet count &gt;100x10^9/L; CR with incomplete platelet recovery (CRp): CR but platelet count &lt;100x10^9/L. CR with incomplete recovery (CRi): CR but platelet count &lt;100x10^9/L or absolute neutrophil count &lt; 1x10^9/L. Partial response (PR): As above except for presence of 6-25% marrow blasts. Lymphoblastic lymphoma (&amp; ALL subtypes with extramedullary disease): CR - disappearance all known disease. PR - &gt;50% decrease in tumor size using sum of product, includes 50% volume decrease in lesions measurable in 3 dimensions. No Response (NR) - No significant change (includes stable disease). Lesions decreased size but &lt;50% or lesions with slight enlargement &lt;25% increase in size. Progressive Disease (PD): Appearance new lesions, 25% or &gt; increase in size existing lesions (&gt;50% if 1 lesion &amp; &lt;2).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response without Platelet Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 cycles of 21 days with 7 day waiting period in between (approximately 28 days) then 30 following last treatment, therefore up to 210 days for completed treatment periods.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HYPER-CVAD</title>
          <description>Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m^2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hours after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage CNS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Bactremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Right Eye Retinal Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Rectum Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hemorrhage Gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Partial Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Perforated Sigmoid Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Flu-Like Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Pain Gallbladder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Acute Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="60" subjects_affected="34" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="54" subjects_affected="32" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Arm Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Soft Tissue Necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Seizures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Hydro-Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Lung Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Soft tissue discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="215"/>
              </event>
              <event>
                <sub_title>Right Subclavian Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="215"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="220"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="220"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hagop Kantarjian, MD./ Chair</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-7026</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

